PCI Pharma Services Announces Major Investment to Expand Development and Manufacturing Capabilities at Tredegar, UK Site

The investment involves an extension to the world-class, award-winning, contained oral solid dosage form manufacturing facility that will double the large-scale granulation and fluid bed drying capacity. It will also create additional space for new potent handling capabilities, additional analytical, and a small-scale processing area to allow early stage non-GMP processing and formulation. The new space is estimated to be completed by late 2021.

“Pharmaceutical and biopharmaceutical companies are innovating drug treatments today at a rapid pace and in greater volume. As the market continues to grow, we’ve seen an increasing number of clients look to us to provide manufacturing services across the spectrum of dosage forms,” said Richard Yarwood, Chief Scientific Officer, PCI Pharma Services. “The expansion at Tredegar will double our large-scale manufacturing capacity to ensure that new and existing customers have their development and supply needs met now and in the future.”

The investment in Tredegar follows news earlier this month of the completed expansion to the Rockford, IL facility to include 30,000+ square feet dedicated to Specialty Drug Product Capabilities, with four high potent compound capable suites and three new secondary packaging areas.

“This latest investment in Tredegar is part of our ongoing business strategy to remain flexible in an ever-changing marketplace to better service our clients as they work to deliver life-changing therapies to patients, such as key oncology compounds which require high potent processing expertise,” said Salim Haffar, CEO, PCI Pharma Services. “Growing our manufacturing capabilities in Tredegar demonstrates our commitment to manufacturing and providing this service to clients who need a supply chain partner throughout the entire process, from drug development to commercialization.”

About the Tredegar Facility

With unparalleled capability in contained manufacture of potent compounds, our Tredegar site excels as PCI’s center of excellence for drug manufacture. Significant investment in cutting edge technologies and world-class award-winning facility design have enabled a truly market leading service for the development and manufacture of clinical and commercial scale products. Services include formulation and analytical development, clinical trial supply, and commercial manufacturing of solid oral dose, powders, liquids and semisolids, supported by in-house packaging and labelling services and on-site testing and release services.

With over 35 years of experience in providing integrated drug development, PCI supports compounds from the earliest stages of development through to commercial launch and ongoing supply. Recognized for our regulatory and export experience, our Tredegar site supplies global markets including Europe, the US, South America and Japan.

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005060/en/